ClinicalTrials.gg
Not yet recruitingNCT07930936Updated Nov 12, 2026

Immunotherapy and Irreversible Electroporation (IRE) in the Treatment of Locally Advanced Pancreatic Adenocarcinoma

A Phase 1 interventional study of 1.0% IP-001 for injection and Irreversible Electroporation in Locally Advanced Pancreatic Adenocarcinoma, sponsored by Robert C. Martin. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Robert C. Martin · Phase 1, Interventional, and Treatment

Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to test the safety, tolerability, and preliminary effectiveness of the study drug, IP-001, in patients with locally advanced pancreatic cancer that is treated with IRE.

Read the detailed description

This is a Phase 1b, single-arm trial designed to evaluate the safety and efficacy of administration of intratumoral IP-001 injection following IRE ablation in patients with Stage III, locally advanced pancreatic adenocarcinoma (LAPC).

02

Conditions studied

  • Locally Advanced Pancreatic Adenocarcinoma
03

In context

Lead sponsor

Robert C. Martin is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years at time of signing Form
  • Diagnosed with clinical stage III pancreatic cancer (per National Comprehensive Cancer Network [NCCN] guidelines)
  • Has undergone standard of care (per NCCN guidelines) /induction base chemotherapy for at least 2 months in duration and demonstrated stable or responsive disease, and completed a of at least 21 days prior to study treatment
  • Pancreatic tumor is measurable (bi-dimensional tumor measurements per 3-phase CT scan). If preoperative CT cannot provide 2-dimensional size criteria, then intra-operative ultrasound will be used for baseline size criteria
  • Is a candidate for irreversible electroporation
  • Able to tolerate surgery
  • > 30 mL/min/1.73 m2
  • /Alanine aminotransferase \< 3 times the (ULN) and total \< 1.5 ULN
  • ≥1.5 × 10⁹/L, count ≥ 100 × 10⁹/L, and ≥ 9 g/dL
  • Stable surgical post-operative course as defined by the operative surgeon ( [ECOG]) of 0 or 1
  • Women of

    1. Must have a negative serum human chorionic gonadotropin pregnancy test prior to irreversible electroporation
    2. Are using highly effective , are not lactating, and agree not to become pregnant prior to and during the trial treatment period and for 187 days after treatment with the drug
  • Men agree not to donate sperm or to father a child during the trial treatment period and for 97 days after treatment with the investigational drug
  • Participants on therapeutic anticoagulation are eligible if therapy can be safely held or bridged to achieve an \< 1.5 per institutional guidelines
  • Adverse events from prior therapy must be resolved to Grade ≤ 1 severity.
  • Able to comprehend and have signed the Informed Consent Form to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Known allergic reaction to shellfish, crabs, crustaceans, or any trial components
  • Participating in another clinical trial for the treatment of pancreatic cancer at the time of screening
  • Are pregnant or currently breastfeeding
  • Class III or IV heart disease
  • Inability to discontinue medications known to prolong the or induce Torsades de Pointes before study entry, with drug-specific discontinuation timing documented
  • Uncontrolled infection requiring antibiotic therapy
  • to heparin
  • Major surgery within 14 days of enrollment
  • Prior high dose radiation therapy defined as total dose of > 5400 cGy
  • Have a cardiac pacemaker or ICD implanted that cannot be deactivated during IRE procedure
  • history of epilepsy or cardiac arrhythmia
  • Have nonremovable implants with metal parts within 1cm of the target lesion
  • Had a myocardial infarction within 3 months prior to enrollment ( date)
  • Actively bleeding, anticoagulated, or have a known or suspected coagulopathy which has not been corrected
  • disease and/or medical condition requiring systemic treatment with that cannot be stopped during treatment
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    1% IP-001 for injection following IRE

    Participants will receive intratumoral injection of 1% IP-001 (diluted to 1 mg/mL, up to 12 mL total) into and around the treated tumor and ablated area immediately following IRE

    Drug: 1.0% IP-001 for injection · Procedure: Irreversible Electroporation

Interventions

  • Participants will receive intratumoral injection of 1% IP-001 (diluted to 1 mg/mL, up to 12 mL total) into and around the treated tumor and ablated area immediately following IRE

  • ProcedureIrreversible Electroporation

    Participants will undergo IRE of the tumor

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of IP-001 administered intratumorally following IRE

    Incidence, severity, and outcomes of adverse events assessed by CTCAE v4.0, clinical assessments, and laboratory test abnormalities, as well as a return to baseline patient reported outcomes.

    Time frame: Day 0 to 90 days after treatment or the start of subsequent anti-cancer therapy, whichever comes first

Secondary outcomes

  1. Progression Free Survival

    Assessed from Treatment Day 0 to the first documented occurrence of progression (local or distant) or death, whichever comes first. Progression will be determined by the investigator's radiological review per RECIST v1.1

    Time frame: Months 12 and 24

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Jan 2030, 37 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2026
First posted
Nov 12, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07930936
Lead sponsor
Robert C. Martin
Responsible party
Robert C. Martin (Director of the Division of Surgical Oncology, University of Louisville) — Sponsor-investigator
First posted
Nov 12, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Robert Martin, MD, PhD
Contact
robert.martin@louisville.edu
502-629-3355
Robert Martin, MD, PhD
principal investigator · University of Louisville

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-dihydrogalactochitosan

Start the discussion